Association between APOA1 gene (rs670) single-nucleotide polymorphism and dyslipidaemia: a systematic review and meta-analysis

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Background: Metabolic syndrome and dyslipidaemia increase the risk of death by two or three times. In this context, the role of apolipoprotein A-I (Apo A-I), the main structural protein of high-density lipoprotein (HDL), stands out, since its anti-inflammatory potential reduces cardiovascular risk. Further, genetic modifications, such as the rs670 single-nucleotide polymorphism (SNP), in the promoter region of the APOA1 gene are associated with the development of cardiovascular events, dyslipidemia, and diabetes, as well as metabolic syndrome. Thus, this study aims to investigate the relation between the occurrence of dyslipidemia and the rs670 SNP genotypes. Methods: An integrative and systematic review was performed with the LitVar² database according to the PRISMA protocol standards. Studies were researched up to August 2025. Then, a meta-analysis was performed using the fixed-effects model, since the study was considered homogeneous based on the I² value (< 50%). Results: Of the 99 found articles in the database, 5 referred to metabolic disorders (n = 7,705-4 Chinese studies and 1 Iranian study) and were published between 2015 and 2018. Three (n = 2,784 patients or 36.13%) of the articles indicated an association between the polymorphic allele and a higher risk of developing dyslipidemia with a relative risk of 1.16 (IC 95% 1.09–1.23, p < 0.01, I² = 0%). Relative risk (IC 95%) was presented, and p < 0.05 was defined as the significance criterion. Discussion: This study reinforces a possible association between the influence of SNP rs670 and dyslipidemia. This emphasizes the importance of conducting further research incorporating a larger and more diverse study group, as well as investigating the genetic and environmental influence on the phenotypic expression of the rs670 SNP.

Keywords

high-density lipoprotein / apolipoprotein A-I / cardiovascular diseases / genetic polymorphism

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Xiao Q, Wang J, Wang L, Ding H. APOA1/C3/A4/A5 Gene Cluster at 11q23.3 and Lipid Metabolism Disorders: From Epigenetic Mechanisms to Clinical Practices. Biomedicines. 2024; 12: 1224.

[2] Introduction to Lipids and Lipoproteins [Internet]. MDText.com, Inc.; c2000-2025 [cited 2025 Sep 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305896/

[3] Torossian A, Genoux A, Cai Z, Jolivet N, Croyal M, Oliveira AR, et al. Plasma apolipoprotein concentrations and occurrence of cardiovascular events in the general population: an exploratory analysis. Atheroscler Plus. 2025; 60: 35-42.

[4] da Costa MDR, Duque BR, Pinheiro NML, Teixeira IMM, Magalhães EP, da Silva FRC, et al. Single nucleotide polymorphism rs670 in the promoter region of the apolipoprotein A-I gene. Gene Protein Dis. 2025; 4: 4354.

[5] Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics. Biomed Pharmacother. 2022; 154: 113634.

[6] Wu Y, Yu Y, Zhao T, Wang S, Fu Y, Qi Y, et al. Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. PLoS One. 2016; 11: e0147946.

[7] Yin RX, Li YY, Lai CQ. Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels. Lipids Health Dis. 2011; 10: 140.

[8] Hsu MC, Chang CS, Lee KT, Sun HY, Tsai YS, Kuo PH, et al. Central obesity in males affected by a dyslipidemia-associated genetic polymorphism on APOA1/C3/A4/A5 gene cluster. Nutr Diabetes. 2013; 3: e61.

[9] Seilhamer JJ, Protter AA, Frossard P, Levy-Wilson B. Isolation and DNA sequence of full-length cDNA and of the entire gene for human apolipoprotein AI-discovery of a new genetic polymorphism in the apo AI gene. DNA. 1984; 3: 309-17.

[10] Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, et al. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet. 2002; 61: 176-84.

[11] de Luis DA, Izaola O, Primo D, Aller R. Implication of the rs670 variant of APOA1 gene with lipid profile, serum adipokine levels and components of metabolic syndrome in adult obese subjects. Clin Nutr. 2019; 38: 407-11.

[12] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.

[13] Wang X, He J, Guo H, Mu L, Hu Y, Ma J, et al. Interactions of six SNPs in APOA1 gene and types of obesity on low HDL-C disease in Xinjiang pastoral area of China. Lipids Health Dis. 2017; 16: 187.

[14] Feng DW, Ma RL, Guo H, He J, Yan YZ, Muratbek, et al. Association of APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) with dyslipidemia in the Kazakhs of Xinjiang. Genet Mol Res. 2016; 15:gmr.15028094.

[15] Wang X, Guo H, Li Y, Wang H, He J, Mu L, et al. Interactions among genes involved in reverse cholesterol transport and in the response to environmental factors in dyslipidemia in subjects from the Xinjiang rural area. PLoS One. 2018; 13: e0196042.

[16] Hosseini-Esfahani F, Mirmiran P, Daneshpour MS, Mehrabi Y, Hedayati M, Soheilian-Khorzoghi M, et al. Dietary patterns interact with APOA1/APOC3 polymorphisms to alter the risk of the metabolic syndrome: the Tehran Lipid and Glucose Study. Br J Nutr. 2015; 113: 644-53.

[17] Wang JL, Gong D, Hu XY, Wu S, Zheng XL, Wu J, et al. ApoA-1 Mimetic Peptide ELK-2A2K2E Decreases Inflammatory Factor Levels Through the ABCA1-JAK2-STAT3-TTP Axis in THP-1-Derived Macrophages. J Cardiovasc Pharmacol. 2018; 72: 60-7.

[18] Block R, Corsetti J, Goldenberg I, Vorobiof G, McNitt S, Ryan D, et al. The common apolipoprotein A-1 polymorphism -75A>G is associated with ethnic differences in recurrent coronary events after recovery from an acute myocardial infarction. Heart Int. 2009; 4: e8.

[19] ALFA Allele Frequency [Internet]. National Library of Medicine; [cited 2025 Nov 27]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs670

[20] Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res. 1990; 31: 1371-7.

[21] Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J Clin Invest. 1992; 89: 1796-800.

[22] Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 2014; 6: 222-30.

[23] Ouimet M, Barrett TJ, Fisher EA. HDL and Reverse Cholesterol Transport. Circ Res. 2019; 124: 1505-18.

[24] Fung KYY, Ho TWW, Xu Z, Neculai D, Beauchemin CAA, Lee WL, et al. Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1. J Lipid Res. 2024; 65: 100530.

[25] Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013; 424: 245-52.

[26] Robichaud S, Rasheed A, Pietrangelo A, Kim AD, Boucher DM, Emerton C, et al. Autophagy Is Differentially Regulated in Leukocyte and Nonleukocyte Foam Cells During Atherosclerosis. Circ Res. 2022; 130: 831-47.

[27] Krishnamurthy HK, Balaguru UM, Pereira M, Jayaraman V, Song Q, Krishna K, et al. Influence of genetic polymorphisms on serum biomarkers of cardiac health. Medicine (Baltimore). 2023; 102: e33953.